PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11008222-4 2000 The results showed that the patients who received ribavirin showed a higher reduction in serum alanine aminotransferase (ALT) activity than patients in the placebo group. Ribavirin 50-59 glutamic--pyruvic transaminase Homo sapiens 95-119 20524482-0 2009 Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy. Ribavirin 60-69 glutamic--pyruvic transaminase Homo sapiens 124-148 17100715-7 2006 RESULTS: In patients treated with ribavirin alone (n = 8), mean alanine aminotransferase (ALT) levels before and after treatment were significantly different (198.4 +/- 147.6 and 104.8 +/- 66.5 IU/L respectively; p < 0.05). Ribavirin 34-43 glutamic--pyruvic transaminase Homo sapiens 64-88 16556180-0 2006 Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Ribavirin 93-102 glutamic--pyruvic transaminase Homo sapiens 188-212 14760885-0 2003 Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Ribavirin 33-42 glutamic--pyruvic transaminase Homo sapiens 137-161 9305674-3 1997 Three randomized, placebo-controlled studies comprising more than 150 patients have shown that therapy with ribavirin alone for 24 to 48 weeks resulted in a significant reduction in serum alanine aminotransferase (ALT) levels during therapy. Ribavirin 108-117 glutamic--pyruvic transaminase Homo sapiens 188-212 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 glutamic--pyruvic transaminase Homo sapiens 171-195 9696489-6 1998 RESULTS: In six of the 15 patients treated with ribavirin, but in none of the controls, serum alanine aminotransferase levels declined by at least 30%. Ribavirin 48-57 glutamic--pyruvic transaminase Homo sapiens 94-118 10342322-1 1999 Ribavirin therapy was initiated at a median of 181 days after liver transplantation in 18 patients with persistent elevation of alanine aminotransferase values and biopsy-proven hepatitis, and continued for 23 months (12-44 months). Ribavirin 0-9 glutamic--pyruvic transaminase Homo sapiens 128-152 22511902-0 2012 Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients. Ribavirin 106-115 glutamic--pyruvic transaminase Homo sapiens 23-47 15566819-10 1995 At the end of 4 weeks of ribavirin treatment, serum levels of alanine aminotransferase (ALT) decreased in all but 1 patient; only 1 patient normalized serum ALT at this time. Ribavirin 25-34 glutamic--pyruvic transaminase Homo sapiens 62-86 7865717-0 1994 Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. Ribavirin 119-128 glutamic--pyruvic transaminase Homo sapiens 33-57 8384433-4 1993 Serum alanine aminotransferase (an indicator of liver damage) was also reduced in animals treated with the two compounds (ribavirin at 32 mg/kg; ribamidine at 100 and 320 mg/kg). Ribavirin 122-131 glutamic--pyruvic transaminase Homo sapiens 6-30 23801888-0 2013 Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Ribavirin 82-91 glutamic--pyruvic transaminase Homo sapiens 0-24 23801888-1 2013 Alanine aminotransferase (ALT) elevation was occassionally observed during the treatment with combination peginterferon alpha plus ribavirin. Ribavirin 131-140 glutamic--pyruvic transaminase Homo sapiens 0-24 9265583-7 1997 Alternative treatment schedules or combination therapy with interferon/ribavirin should be considered in subjects with normalized alanine aminotransferase (ALT) levels, but who are still viremic after three months of therapy, as well as in relapsers and in non-responders. Ribavirin 71-80 glutamic--pyruvic transaminase Homo sapiens 130-154 22103907-0 2012 Pegylated interferon alpha-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. Ribavirin 35-44 glutamic--pyruvic transaminase Homo sapiens 99-123 21269381-0 2011 Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. AIM: Elevation of alanine aminotransferase (ALT) levels during pegylated-interferon (peg-IFN) plus ribavirin therapy in patients with chronic hepatitis C [CHC] is a problem that cannot be disregarded. Ribavirin 103-112 glutamic--pyruvic transaminase Homo sapiens 29-53 21269381-0 2011 Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. AIM: Elevation of alanine aminotransferase (ALT) levels during pegylated-interferon (peg-IFN) plus ribavirin therapy in patients with chronic hepatitis C [CHC] is a problem that cannot be disregarded. Ribavirin 249-258 glutamic--pyruvic transaminase Homo sapiens 29-53 21269381-0 2011 Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. AIM: Elevation of alanine aminotransferase (ALT) levels during pegylated-interferon (peg-IFN) plus ribavirin therapy in patients with chronic hepatitis C [CHC] is a problem that cannot be disregarded. Ribavirin 249-258 glutamic--pyruvic transaminase Homo sapiens 168-192